NuCana Reports Positive Phase 2 Results for NUC-7738 in PD-1-Resistant Melanoma

Reuters12-10

NuCana Reports Positive Phase 2 Results for NUC-7738 in PD-1-Resistant Melanoma

NuCana plc has announced new clinical data from its ongoing Phase 2 expansion study evaluating NUC-7738 in combination with pembrolizumab for patients with PD-1 inhibitor-resistant cutaneous melanoma. The results were presented at the ESMO Immuno-Oncology Congress 2025. As of the most recent analysis, the study has treated nine patients in the Expansion Cohort, with plans to enroll up to 28 additional patients. Combined with the Dose Confirmation Cohort, the total dataset may include up to 40 patients. The data indicate ongoing clinical activity, including two partial responses (one confirmed) and seven cases of stable disease, with one patient achieving a complete metabolic response. No new safety signals have been observed, and several patients remain on therapy with durable disease control. The company states that these findings support ongoing enrollment and further clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9599650-en) on December 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590799582?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-10 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590799582","market":"nz","top_or_hot":-1,"title":"NuCana Reports Positive Phase 2 Results for NUC-7738 in PD-1-Resistant Melanoma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NuCana Reports Positive Phase 2 Results for NUC-7738 in PD-1-Resistant Melanoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NuCana plc has announced new clinical data from its ongoing Phase 2 expansion study evaluating NUC-7738 in combination with pembrolizumab for patients with PD-1 inhibitor-resistant cutaneous melanoma. The results were presented at the ESMO Immuno-Oncology Congress 2025. As of the most recent analysis, the study has treated nine patients in the Expansion Cohort, with plans to enroll up to 28 additional patients. Combined with the Dose Confirmation Cohort, the total dataset may include up to 40 patients. The data indicate ongoing clinical activity, including two partial responses (one confirmed) and seven cases of stable disease, with one patient achieving a complete metabolic response. No new safety signals have been observed, and several patients remain on therapy with durable disease control. The company states that these findings support ongoing enrollment and further clinical development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9599650-en) on December 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NuCana Reports Positive Phase 2 Results for NUC-7738 in PD-1-Resistant Melanoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuCana Reports Positive Phase 2 Results for NUC-7738 in PD-1-Resistant Melanoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-10 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NuCana Reports Positive Phase 2 Results for NUC-7738 in PD-1-Resistant Melanoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NuCana plc has announced new clinical data from its ongoing Phase 2 expansion study evaluating NUC-7738 in combination with pembrolizumab for patients with PD-1 inhibitor-resistant cutaneous melanoma. The results were presented at the ESMO Immuno-Oncology Congress 2025. As of the most recent analysis, the study has treated nine patients in the Expansion Cohort, with plans to enroll up to 28 additional patients. Combined with the Dose Confirmation Cohort, the total dataset may include up to 40 patients. The data indicate ongoing clinical activity, including two partial responses (one confirmed) and seven cases of stable disease, with one patient achieving a complete metabolic response. No new safety signals have been observed, and several patients remain on therapy with durable disease control. The company states that these findings support ongoing enrollment and further clinical development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9599650-en) on December 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL6Zx6dm:1","article_id":"2590799582","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590799582","pubTimestamp":1765371618,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NuCana plc has announced new clinical data from its ongoing Phase 2 expansion study evaluating NUC-7738 in combination with pembrolizumab for patients with PD-1 inhibitor-resistant cutaneous melanoma. The results were presented at the ESMO Immuno-Oncology Congress 2025. As of the most recent analysis, the study has treated nine patients in the Expansion Cohort, with plans to enroll up to 28 additional patients. Combined with the Dose Confirmation Cohort, the total dataset may include up to 40 patients. The data indicate ongoing clinical activity, including two partial responses  and seven cases of stable disease, with one patient achieving a complete metabolic response. No new safety signals have been observed, and several patients remain on therapy with durable disease control. The company states that these findings support ongoing enrollment and further clinical development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4139":"生物科技","NCNA":"Nucana PLC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","NDAQ":"纳斯达克OMX交易所","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD"},"translate_title":"NuCana报告NUC-7738治疗PD-1耐药黑色素瘤的积极2期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"NCNA":0.9},"content_text":"NuCana Reports Positive Phase 2 Results for NUC-7738 in PD-1-Resistant Melanoma\n    \n\n        NuCana plc has announced new clinical data from its ongoing Phase 2 expansion study evaluating NUC-7738 in combination with pembrolizumab for patients with PD-1 inhibitor-resistant cutaneous melanoma. The results were presented at the ESMO Immuno-Oncology Congress 2025. As of the most recent analysis, the study has treated nine patients in the Expansion Cohort, with plans to enroll up to 28 additional patients. Combined with the Dose Confirmation Cohort, the total dataset may include up to 40 patients. The data indicate ongoing clinical activity, including two partial responses (one confirmed) and seven cases of stable disease, with one patient achieving a complete metabolic response. No new safety signals have been observed, and several patients remain on therapy with durable disease control. The company states that these findings support ongoing enrollment and further clinical development.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9599650-en) on December 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590799582","isCrawlerRequest":true}